Metrics Adds Serialization Capabilities to North Carolina Site
In preparation for the upcoming US Drug Supply Chain Security Act deadline, Metrics Contract Services has expanded serialization capabilities at its oral solid-dose commercial manufacturing site in Greenville, NC.
On Nov. 12, 2018, Metrics Contract Services, a division of Mayne Pharma Group, announced the qualification of two commercial bottling lines for serialization at its new $80-million oral solid-dose commercial manufacturing site in Greenville, NC.
The company reports that capacity has more than doubled as part of the Greenville site expansion. One bottling line is dedicated for clinical packaging, and two commercial bottling lines have been qualified for serialization. The newly installed equipment includes a New Jersey machine with an automated case packer and palletizer (IMA Group). The new commercial facility has space available to add a third commercial packaging line as needed to support future growth, according to Metrics.
This expansion marks the conclusion of several years of preparation and investment to comply with the new requirements associated with the US Drug Supply Chain Security Act, which are subject to enforcement starting November 28, 2018.
Additionally, Mayne Pharma has implemented Optel systems on the packaging lines and is using TraceLink as its level 4 and 5 provider to manage the enterprise and network connectivity.
Source: Metrics Contract Services
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
